What 4 Analyst Ratings Have To Say About IGM Biosciences
Portfolio Pulse from Benzinga Insights
Four analysts have provided varied opinions on IGM Biosciences (NASDAQ:IGMS) over the past quarter, with ratings ranging from somewhat bullish to indifferent. The average 12-month price target has increased by 9.52% to $17.25. Key analysts have either raised or maintained their ratings, with price targets ranging from $12.00 to $25.00. Despite challenges in revenue growth and below-average ROE and ROA, the company maintains a balanced debt approach.
August 15, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have mixed views on IGM Biosciences, with recent ratings ranging from somewhat bullish to indifferent. The average 12-month price target has increased by 9.52% to $17.25, with individual targets ranging from $12.00 to $25.00. Despite revenue challenges and below-average ROE and ROA, the company maintains a balanced debt approach.
The increase in the average price target and the somewhat bullish ratings from key analysts suggest a positive short-term outlook for IGMS. However, the company's revenue challenges and below-average ROE and ROA may temper this optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100